Meningococcal glycoconjugate vaccines

References

• Viesseux G. Mémoire sur la maladie qui a régné à Genève au printemps de 1805. J Med Chir Farm 1805; 11:143 - 182
   Google Scholar
• Wu HM, Harcourt BH, Hatcher CP, Wei SC, Novak RT, Wang X, et al. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med 2009; 360:886 - 892
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365 - 367
   PubMed Web of Science ®Google Scholar
• European Union Invasive Bacterial Infections Surveillance (EU-IBIS) Network. Invasive Neisseria meningitidis in Europe 2006 2007; May 13 2010 London Health Protection Agency http://www.euibis.org/documents/2006_meningo.pdf.
   Google Scholar
• Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187 - 195
   PubMed Web of Science ®Google Scholar
• Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenze protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J 2009; 28:97 - 108
   PubMed Web of Science ®Google Scholar
• Dinleyici EC, Yargic ZA. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Expert Rev Vaccines 2009; 8:977 - 986
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices (ACIP). Prevention and Control of Meningococcal Disease. MMWR 2005; 54:1 - 21
   PubMedGoogle Scholar
• Center for Disease Control and Prevention. Licensure of a meningococcal Conjugate Vaccine (Menveo) and Guidance for Use—Advisory Committee on Immunization Practices 2010; May 13 2010 Available on-line: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5909a5.htm.
   Google Scholar
• European Medicine Agency. EPARs for authorised medicinal products for human use—Menveo May 13 2010 Available on: http://www.ema.europa.eu/humandocs/Humans/EPAR/menveo/menveo.htm
   Google Scholar
• Granoff MD, Harrison LH, Borrow R. Plotkin SA, Orenstein WA, Offit PA. Meningococcal Vaccines. Vaccines 2008; 5th Edition Philadelphia Saunders 399 - 434
   Google Scholar
• Pollard AJ, Levin M. Vaccines for prevention of meningococcal disease. Pediatr Infect Dis J 2000; 19:333 - 344
   PubMed Web of Science ®Google Scholar
• Gold R, Goldschneider I, Lepow ML, Draper TF, Randolph M. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis 1978; 137:112 - 121
   PubMed Web of Science ®Google Scholar
• Caugant DA, Maiden MC. Meningococcal carriage and disease—population biology and evolution. Vaccine 2009; 27:64 - 70
   PubMed Web of Science ®Google Scholar
• Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia and Neisseria meningitidis. Lancet 2007; 369:2196 - 2210
   PubMed Web of Science ®Google Scholar
• Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev 2007; 31:3 - 14
   PubMed Web of Science ®Google Scholar
• Lo H, Tang CM, Exley RM. Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis 2009; 9:418 - 427
   PubMed Web of Science ®Google Scholar
• Kolb-Mäurer A, Unkmeir A, Kämmerer U, Hübner C, Leimbach T, Stade A, et al. Interaction of Neisseria meningitidis with human dendritic cells. Infect Immun 2001; 69:6912 - 6922
   PubMed Web of Science ®Google Scholar
• Unkmeir A, Kämmerer U, Stade A, Hübner C, Haller S, Kolb-Mäurer A, et al. Lipooligosaccharide and polysaccharide capsule: virulence factors of Neisseria meningitidis that determine meningococcal interaction with human dendritic cells. Infect Immun 2002; 70:2454 - 2462
   PubMed Web of Science ®Google Scholar
• Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, et al. The changing epidemiology of meningococcal disease in the United States 1992–1996. J Infect Dis 1999; 180:1894 - 1901
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27:51 - 63
   PubMed Web of Science ®Google Scholar
• Pizza M, Scarlato V, Masignani V, Giuliani MM, Aricò B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by wholegenome sequencing. Science 2000; 287:1816 - 1820
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000; 3:445 - 450
   PubMed Web of Science ®Google Scholar
• Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004; 72:2088 - 2100
   PubMed Web of Science ®Google Scholar
• Zhu D, Barniak V, Zhang Y, Green B, Zlotnick G. Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis. Vaccine 2006; 24:5420 - 5425
   PubMed Web of Science ®Google Scholar
• Richmond P, Marshall H, Nissen MD, Lambert S, Jones T, Gruber W, Arora A. A randomized, observerblinded, active-control, phase 1 trial of meningococcal serogroup B rLP2086 vaccine in healthy children and adolescents aged 8 to 14 years Poster presented at: 16th International Pathogenic Neisseria Conference 2008 Rotterdam, the Netherlands 212
   Google Scholar
• Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010; 362:1511 - 1520
   PubMed Web of Science ®Google Scholar
• Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8:851 - 861
   PubMed Web of Science ®Google Scholar
• Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378 - 1388
   PubMed Web of Science ®Google Scholar
• Cartwright K. Cartwright K. Meningococcal carriage and disease. Meningococcal Disease 1995; New York John Wiley & Sons Ltd 115 - 146
   Google Scholar
• Advisory Committee on Immunization Practices (ACIP). Prevention and control meningococcal disease. Recommendations of the AICP. MMWR Recomm Rep 2000; 49:1 - 10
   Google Scholar
• WHO. Meningococcal meningitis May 13 2010 Fact Sheet No.141.2003. http://www.who.int/mediacenter/factsheets/fs141/en/index.html.
   Google Scholar
• Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada 1990–1994. Clin Infect Dis 1998; 26:1159 - 1164
   PubMed Web of Science ®Google Scholar
• Goldacre MJ, Roberts SE, Yeates D. Case fatality rates for meningococcal disease in an English population 1963–98: database study. BMJ 2003; 327:596 - 597
   PubMed Web of Science ®Google Scholar
• Kimmel SR. Prevention of meningococcal disease. Am Fam Physician 2005; 72:2049 - 2056
   PubMed Web of Science ®Google Scholar
• Sophian A, Black J. Prophylactic vaccination against epidemic meningitis. JAMA 1912; 59:527 - 532
   Google Scholar
• Gates FL. A report on antimeningitis vaccination and observations on agglutinins in the blood of chronic meningococcus carriers. J exp Med 1918; 28:449 - 474
   PubMedGoogle Scholar
• Artenstein MS, Schneider H, Tingley MD. Meningococcal infections. 1. Prevalence of serogroups causing disease in US Army personnel in 1964–70. Bull World Health Organ 1971; 45:275 - 278
   PubMed Web of Science ®Google Scholar
• Miller JW, Siess EE, Feldman HA. In vivo and in vitro resistance to sulfadiazine in strains of Neisseria meningitidis. Jama 1963; 186:139 - 141
   PubMed Web of Science ®Google Scholar
• Gotschlich EC, Liu TY, Artenstein MS. Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B and group C meningococcal polysaccharides. J Exp Med 1969; 129:1349 - 1365
   PubMed Web of Science ®Google Scholar
• Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969; 129:1367 - 1384
   PubMed Web of Science ®Google Scholar
• Mäkelä PH, Käyhty H, Weckström P, Sivonen A, Renkonen OV. Effect of group-A meningococcal vaccine in army recruits in Finland. Lancet 1975; 2:883 - 886
   PubMed Web of Science ®Google Scholar
• Peltola H, Mäkelä H, Käyhty H, Jousimies H, Herva E, Hällström K, et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977; 297:686 - 691
   PubMed Web of Science ®Google Scholar
• Rosenstein N, Levine O, Taylor JP, Evans D, Plikaytis BD, Wenger JD, Perkins BA. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA 1998; 279:435 - 439
   PubMed Web of Science ®Google Scholar
• Griffiss JM, Brandt BL, Broud DD. Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines. Infect Immun 1982; 37:205 - 208
   PubMed Web of Science ®Google Scholar
• Ambrosch F, Wiedermann G, Crooy P, George AM. Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine. Bull World Health Organ 1983; 61:317 - 323
   PubMed Web of Science ®Google Scholar
• Poland GA. Prevention of meningococcal Disease. Current Use of Polysaccharide and conjugate vaccines. CID 2010; 50:45 - 53
   PubMed Web of Science ®Google Scholar
• Bulukha OO, Rosenstein N. National Center for Infectious Diseases, Center for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMRW Recomm Rep 2005; 54:1 - 21
   Google Scholar
• Biselli R, Fattorossi A, Matricardi PM, Nisini R, Stroffolini T, D'Amelio R. Dramatic reduction of meningococcal meningitis among military recruits in Italy after introduction of specific vaccination. Vaccine 1993; 11:578 - 581
   PubMed Web of Science ®Google Scholar
• Robbins JB, Schneerson R, Gotschlich EC, Mohammed I, Nasisi A, Chippaux JP, et al. Menigococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines. Bull World Health Organ 2003; 81:745 - 750
   PubMed Web of Science ®Google Scholar
• Birmingham ME, Lewis RF, Perea W, Nelson CB, Kabore A, Tarantola D. Routine vaccination with polysaccharide meningococcal vaccines is an ineffective and possibly harmful strategy. Bull World Health Organ 2003; 81:751 - 755
   Web of Science ®Google Scholar
• Twumasi P Jr, Kumah S, Leach A, O'Dempsey TJ, Ceesay SJ, Todd J, et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995; 171:632 - 638
   PubMed Web of Science ®Google Scholar
• Lieberman JM, Chiu SS, Wong VK, Partidge S, Chang SJ, Chiu CY, et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharideprotein conjugate vaccine in young children. A randomized controlled trial. JAMA 1996; 275:1499 - 1503
   PubMed Web of Science ®Google Scholar
• Avery OT, Goebel WF. Chemo-immunological studies on conjugate carbohydrate proteins. II. Immunological specificity of synthetic sugar protein antigen. J Exp Med 1929; 50:533 - 550
   PubMedGoogle Scholar
• Ada G, Isaacs D. Carbohydrate-protein conjugate vaccines. Clin Microbiol Infect 2003; 9:79 - 85
   PubMed Web of Science ®Google Scholar
• Lindberg AA. Glycoprotein conjugate vaccines. Vaccine 1999; 17:28 - 36
   PubMed Web of Science ®Google Scholar
• Breukels M, Zandvoort A, Van Den Dobblesteen GP, et al. Pneumococcal conjugate vaccines overcome splenic dependency of antibody response to pneumococcal polysaccharides. Infect Immun 2001; 69:7583 - 7587
   PubMed Web of Science ®Google Scholar
• Stein KE. Thymus-independent and thymus-dependent response to polysaccharide antigens. J Infect Dis 1992; 165:49 - 52
   PubMed Web of Science ®Google Scholar
• Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenze type b (Hib) disease in the Hib vaccine era. JAMA 1993; 269:221 - 226
   PubMed Web of Science ®Google Scholar
• Peltola H, Kipli T, Anttila M. Rapid disappearance of Haemophilus influenze type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 1992; 340:592 - 594
   PubMed Web of Science ®Google Scholar
• Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997; 337:970 - 976
   PubMed Web of Science ®Google Scholar
• Barbour ML, Mayon-White RT, Coles C, Crook DWM, Moxon ER. The impact of conjugate vaccine on carriage of Haemophilus influenze type b. J Infect Dis 1995; 171:93 - 98
   PubMed Web of Science ®Google Scholar
• Jonsdotir KE, Steingrimsson O, Olafsson O. Immunisation in infants in Iceland against Haemophilus influenze type b. Lancet 1992; 340:252 - 253
   Web of Science ®Google Scholar
• Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenze PD conjugate vaccine: Synflorix. Expert Rev Vaccines 2009; 8:1479 - 1500
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène JP, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenze protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009; 28:66 - 76
   PubMed Web of Science ®Google Scholar
• Lin FYC, Vo AH, Khiem HB, et al. The efficacy of a Samonella typhi Vi conjugate vaccine in two to five year-old children. N Engl J Med 2001; 344:1263 - 1269
   PubMed Web of Science ®Google Scholar
• Baker CJ, Paoletti LC, Rench MA, et al. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B streptococcus in healthy women. J Infect Dis 2000; 182:1129 - 1138
   PubMed Web of Science ®Google Scholar
• Shinenfield H, Black S, Fattom A, et al. Use of a staphylococcus aureus conjugate vaccine in patients receiving heamodialysis. N Engl J Med 2002; 346:491 - 496
   PubMed Web of Science ®Google Scholar
• Cryz S Jr, Que JO, Cross S, Furer E. Synthesis and characterisation of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine. Vaccine 1995; 13:449 - 453
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Perrett KP, Beverly PC. Mantaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9:213 - 220
   PubMed Web of Science ®Google Scholar
• Harrison LH. Vaccine prevention of meningococcal disease: making slow progress. Clin Infect Dis 2006; 43:1395 - 1397
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357:195 - 196
   PubMed Web of Science ®Google Scholar
• Trotter CL, Chandra M, Cano R, Larrauri A, Ramsay ME, Brehony C, et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007; 31:27 - 36
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365 - 367
   PubMed Web of Science ®Google Scholar
• Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, Borrow R, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006; 55:887 - 896
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavòn AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccis on carriage and herd immunity. J Infect Dis 2008; 197:737 - 743
   PubMed Web of Science ®Google Scholar
• Perret KP, Winter AP, Kibowana E, Jin C, John TM, Yu LM, et al. Only one quarter of UK primary school children remain seroprotected against serogroup C meningococcal Disease despite immunisation in 1999–2000 28th Annual Meeting of ESPID—Nice May 4–8 2010 France 26
   Google Scholar
• Borrow R, Andrews N, Findlow H, Waight P, Southern J, Crowley-Luke A, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenze type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010; 17:154 - 159
   PubMed Web of Science ®Google Scholar
• Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005; 159:907 - 913
   PubMed Web of Science ®Google Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C congiugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003; 10:780 - 786
   PubMedGoogle Scholar
• Food and Drug Administration. Product approval information licensing action 2005; Rockville, MD US Department of Health and Human Services, Food and Drugs Administration, Center for Biologics Evaluation and Research Available at http://www.fda.gov/cber/products/mpdtave011405.htm.htm.
   Google Scholar
• Pichichero M, Casey J, Blatter M, Rothstein E, Ryall R, Bybel M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two to ten year-old children. Pediatr Infect Dis J 2005; 24:57 - 62
   PubMed Web of Science ®Google Scholar
• Rennels M, King J Jr, Ryall R, Papa T, Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004; 23:429 - 435
   PubMed Web of Science ®Google Scholar
• Rennels M, King J Jr, Ryall R, Manoff S, Papa T, Weddle A, Froeschle J. Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers. Pediatr Infect Dis J 2002; 21:978 - 979
   PubMed Web of Science ®Google Scholar
• Finn A. Bacterial polysaccharide-protein conjugate vaccines. Br Med Bull 2004; 70:1 - 14
   Google Scholar
• Center for Disease Control and Prevention. Update Guillain-Barre syndrome among recipients of menactra meningococcal conjugate vaccine, United States, June 2005. MMWR 2006; 55:1120
   PubMedGoogle Scholar
• Center for Disease Control and Prevention. Recommended immunization schedules for persons aged 0 through 18 years—United States 2009. MMWR 2009; 57:1 - 4
   Google Scholar
• Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008; 299:173 - 184
   PubMed Web of Science ®Google Scholar
• Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2–10 years of age. Vaccine 2010; 28:657 - 663
   PubMed Web of Science ®Google Scholar
• Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009; 49:1 - 10
   PubMed Web of Science ®Google Scholar
• Gill CJ, Karsten A, Bedell L, De Tora L, Dull P. Safety and immunogenicity in clinical trials of MENVEO quadrivalent meningococcal glycoconjugate vaccine in adults up to 65 years old 28th Annual Meeting of ESPID—Nice May 4–8 2010 France 380
   Google Scholar
• Gasparini R, Conversano M, Bona G, Gabutti G, Anemona A, Dull PM, et al. Randomized trial on the safety, tolerability and immunogenicity of MenACWYCRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol 2010; 17:537 - 544
   PubMed Web of Science ®Google Scholar
• Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 2010; 28:3171 - 3179
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years. Vaccine 2009; 27:161 - 168
   PubMed Web of Science ®Google Scholar
• Knuf M, Romain O, Krause KH, Kindler K, Walther U, Tran M, et al. The candidate MENACWY-TT conjugate vaccine is immunogenic and has an acceptable safety profile in children 2–10 years of age 28th Annual Meeting of ESPID—Nice May 4–8 2010 France 391
   Google Scholar
• Maurer H, Knuf M, Pantazil-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer L, et al. Co-administration of MENACWY-TT conjugate vaccine with DTPA-HBV-IPV/HIB vaccine does not impair immunoresponse to DTPA-HBV-IPV/HIB and has acceptable safety profile 28th Annual Meeting of ESPID—Nice May 4–8 2010 France 398
   Google Scholar
• Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Immunogenicity and safety of the coadministration of MENACWT-TT conjugate vaccine with MMRV in toddlers 28th Annual Meeting of ESPID—Nice May 4–8 2010 France 432
   Google Scholar
• US National Institutes of Health Clinical Trials Delivered via RSS. Study on the impact of Vaccination with a Conjugate Vaccine on Meningococcal Carriage Available on: http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01119482.
   Google Scholar
• WHO—Fact sheets. Development of mew vaccines Available on: http://www.who.int/mediacentre/factsheets/fs289/en/.
   Google Scholar
• MVP—Meningitis Vaccine Project. Timeline. Put a end to a century of epidemics Available on: http://www.meningvax.org/timeline.php
   Google Scholar
• Kshirsagar N, Mur N, Thatte U, Gogtay N, Viviani S, Préziosi MP, et al. Safety, immunogenicity and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007; 3:25 101 - 107
   Web of Science ®Google Scholar
• WHO—News releases. Improved meningitis vaccine for Africa could signal end to deadly scourge Available on: http://www.who.int/mediacentre/news/releases/2007/pr28/en/.
   Google Scholar
• UNICEF WCARO. African Health Ministries to introduce new vaccines to prevent deadly meningitis epidemics Available on: httpo://www.unicef.org/wcaro/2009_2615.html.
   Google Scholar
• Moszynski P. New meningitis A vaccine is hailed as a “breakthrough” for 430 million people at risk. BMJ 2010; 3552
   Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20:58 - 67
   PubMed Web of Science ®Google Scholar
• Health Protection Agency. Guidance for public health management of meningococcal disease in the UK Health Protection Agency Meningococcus Forum Updated August 2006 May 19 2010 Available on: http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947389261.
   Google Scholar
• Center for Disease Control and Prevention (CDC). Prevention and Control of Meningococcus Disease. Recommendations of the Advisory Committee on Immunization Practices (AICP). MMWR 2005; 54:1 - 21
   PubMedGoogle Scholar
• Center for Disease Control and Prevention (CDC). Updated Recommendations from the Advisory Committee on Immunization Practices (AICP) for Revaccination of Persons at Prolonged Increased Risk for Meningococcal Disease. MMWR 2009; 58:1042 - 1043
   PubMedGoogle Scholar
• Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA 2001; 286:688 - 693
   PubMed Web of Science ®Google Scholar
• Harrison LH, Dwyer DM, Maples CT, Billmann L. Risk of meningococcal infection in college students. JAMA 1999; 281:1906 - 1910
   PubMed Web of Science ®Google Scholar
• CDC. Laboratory-acquired meningococcal disease—United States 2000. MMWR 2002; 51:141 - 144
   PubMedGoogle Scholar
• Brundage JF, Zollinger WD. Vedros NA. Evolution of meningococcal disease epidemiology in the US Army. Evolution of meningococcal disease 1987; 1:Boca Raton, FL CRC Press Inc 5 - 25
   Google Scholar
• Riedo FX, Plikaytis BD, Broome CV. Epidemiology and prevention of meningococcal disease. Pediatr Infect Dis J 1995; 14:643 - 657
   PubMed Web of Science ®Google Scholar
• Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991; 4:359 - 395
   PubMed Web of Science ®Google Scholar
• Francke EL, Neu HC. Postsplenectomy infection. Surg Clin North Am 1981; 61:135 - 155
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention (CDC). Licensure of a Meningococcal Conjugate Vaccine (Menveo) and Guidance for use—Advisory Committee on Immunization Practices (ACIP) 2010. MMWR 2010; 59:273
   PubMedGoogle Scholar
• National Advisory Committee on Immunization (NACI). Statement on recommended use of meningococcal vaccines. CCDR 2001; 27:2 - 36
   Google Scholar
• National Advisory Committee on Immunization (NACI). Update on meningococcal C conjugate vaccines. CCDR 2005; 31:1 - 4
   Google Scholar
• D'Ancona F, Alfonsi V, Caporali M, Ranghiasci A, Ciofi degli Atti ML. Pneumococcal conjugate, meningococcal C and varicella vaccination in Italy. Euro Surveill 2007; 12
   PubMedGoogle Scholar
• Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135 and X strains from Africa. J Infect Dis 2009; 199:1360 - 1368
   PubMed Web of Science ®Google Scholar
• Pastor P, Medley FB, Murphy TV. Meningococcal disease in Dallas County, Texas: results of a six-year population-based study. Pediatr Infect Dis J 2000; 19:324 - 328
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in Neisseria meningitidis disease epidemiology in the United States 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184 - 191
   PubMed Web of Science ®Google Scholar
• Pelton SI. Conjugate Meningococcal Vaccines: Lifesaving or Inefficient Use or Both—No easy Answer. CID 2010; 50:192 - 193
   PubMed Web of Science ®Google Scholar
• De Wals P. Immunization strategies for the control of serogroup C meningococcal disease in developed countries. Expert Rev Vaccines 2006; 5:269 - 275
   PubMed Web of Science ®Google Scholar
• Trotter C, Borrow R, Andrews N, Miller E. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the prevaccination era. Vaccine 2003; 21:1094 - 1098
   PubMed Web of Science ®Google Scholar
• Gasparini R, Rizzetto R, Sasso T, Rizzitelli E, Manfredi P, Risso D, et al. Seroprevalence of bactericidal antibody against Neisseria meningitidis serogroup C in pre-vaccinal era: the Italian epidemiological scenario. Vaccine 2009; 27:3435 - 3438
   PubMed Web of Science ®Google Scholar